# 2026-16728: Bladder Cancer Lights Get Fancy Cysto Rename from FDA

2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2026-08-17, effective Either electronic or written comments on the proposed order must be submitted by October 16, 2026. Please see Section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.; PRIA reads it as touching household money (as of 2026-08-24).

- Canonical: https://policyrisk.com/federal-register/2026-16728
- As of: 2026-08-24
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16728
- Title: Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 53209
- Published: 2026-08-17
- Effective: Either electronic or written comments on the proposed order must be submitted by October 16, 2026. Please see Section X of this document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order based on this proposed order.
- Comments close: 2026-10-16
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-08-24

## In one line

Bladder Cancer Lights Get Fancy Cysto Rename from FDA

## Summary

The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.

## Effects PRIA read

- Manufacturers Shift from PMA to 510(k): benefit, high. If this proposal is finalized, companies that make these cystoscopic systems will no longer have to submit a premarket approval (PMA) and instead will submit a 510(k) premarket notification and receive clearance before marketing. FDA says the 510(k) pathway is less burdensome and more cost-effectiv…
- Potentially Faster Patient Access: benefit, medium. FDA is proposing to reclassify these devices from class III to class II so they would be cleared through 510(k) rather than approved through PMA. FDA says a 510(k) typically results in a shorter premarket review timeline than a PMA, which may provide more timely patient access to cystoscopic system…
- Devices Identified as Prescription Products: benefit, low. FDA proposes that the device type be identified as prescription devices and, if finalized, they would be subject to prescription labeling requirements under 21 CFR 801.109. That means these cystoscopic systems must be labeled and distributed only under a prescription, consistent with other prescrip…
- Special Controls to Mitigate Device Risks: benefit, medium. FDA proposes to impose special controls for these cystoscopic systems as class II devices to mitigate identified risks, including false positive/negative results, device failure or malfunction, electrical/thermal/light injuries, interference with other devices, infection/cross-contamination, and ad…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-16728 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/17/2026-16728/gastroenterology-urology-devices-reclassification-of-diagnostic-endoscopic-light-source-systems-to)
- [2026-16728 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-17/pdf/2026-16728.pdf)

## Related
- [Previous: 2026-16724, Receipt of Pesticide Petitions Filed for Residues of Pesticide Chemicals in or…](https://policyrisk.com/federal-register/2026-16724)
- [Next: 2026-16729, Medical Devices; Classification of Accessories Distinct From Other Devices; Pro…](https://policyrisk.com/federal-register/2026-16729)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16728 (as of 2026-08-24).
